|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
3
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cai M, Song XL, Li XA, Chen M, Guo J, Yang
DH, Chen Z and Zhao SC: Current therapy and drug resistance in
metastatic castration-resistant prostate cancer. Drug Resist Updat.
68:1009622023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xiao Y, Liu P, Wei J, Zhang X, Guo J and
Lin Y: Recent progress in targeted therapy for non-small cell lung
cancer. Front Pharmacol. 14:11255472023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lev S: Targeted therapy and drug
resistance in triple-negative breast cancer: The EGFR axis. Biochem
Soc Trans. 48:657–665. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wagh K, Stavreva DA, Upadhyaya A and Hager
GL: Transcription factor dynamics: One molecule at a time. Annu Rev
Cell Dev Biol. 39:277–305. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mann R and Notani D: Transcription factor
condensates and signaling driven transcription. Nucleus.
14:22057582023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mazzocca M, Colombo E, Callegari A and
Mazza D: Transcription factor binding kinetics and transcriptional
bursting: What do we really know? Curr Opin Struct Biol.
71:239–248. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Krebs AR: Studying transcription factor
function in the genome at molecular resolution. Trends Genet.
37:798–806. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
García-Gutiérrez L, Delgado MD and León J:
MYC oncogene contributions to release of cell cycle brakes. Genes
(Basel). 10:2442019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nair SK and Burley SK: X-ray structures of
Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation
by proto-oncogenic transcription factors. Cell. 112:193–205. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Llombart V and Mansour MR: Therapeutic
targeting of ‘undruggable’ MYC. EBioMedicine. 75:1037562022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Y, Xue K, Li Z, Zheng W, Dong W, Song
J, Sun S, Ma T and Li W: [Corrigendum] c-Myc regulates the
CDK1/cyclin B1 dependent-G2/M cell cycle progression by histone H4
acetylation in Raji cells. Int J Mol Med. 44:19882019.PubMed/NCBI
|
|
15
|
Carabet LA, Rennie PS and Cherkasov A:
Therapeutic Inhibition of Myc in cancer. Structural bases and
computer-aided drug discovery approaches. Int J Mol Sci.
20:1202018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–764. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gabay M, Li Y and Felsher DW: MYC
activation is a hallmark of cancer initiation and maintenance. Cold
Spring Harb Perspect Med. 4:a0142412014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sayyadi M, Safaroghli-Azar A,
Pourbagheri-Sigaroodi A, Abolghasemi H, Anoushirvani AA and Bashash
D: c-Myc inhibition using 10058-F4 increased the sensitivity of
acute promyelocytic leukemia cells to arsenic trioxide via blunting
PI3K/NF-κB axis. Arch Med Res. 51:636–644. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kumari N, Das K, Sharma S, Dahal S, Desai
SS, Roy U, Sharma A, Manjunath M, Gopalakrishnan V, Retheesh ST, et
al: Evaluation of potential role of R-loop and G-quadruplex DNA in
the fragility of c-MYC during chromosomal translocation associated
with Burkitt's lymphoma. J Biol Chem. 299:1054312023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giacomini A, Taranto S, Gazzaroli G,
Faletti J, Capoferri D, Marcheselli R, Sciumè M, Presta M, Sacco A
and Roccaro AM: The FGF/FGFR/c-Myc axis as a promising therapeutic
target in multiple myeloma. J Exp Clin Cancer Res. 43:2942024.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu C, Jiang K, Ding Y, Yang A, Cai R, Bai
P, Xiong M, Fu C, Quan M, Xiong Z, et al: Kindlin-2 enhances c-Myc
translation through association with DDX3X to promote pancreatic
ductal adenocarcinoma progression. Theranostics. 13:4333–4355.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hua Q, Jin M, Mi B, Xu F, Li T, Zhao L,
Liu J and Huang G: LINC01123, a c-Myc-activated long non-coding
RNA, promotes proliferation and aerobic glycolysis of non-small
cell lung cancer through miR-199a-5p/c-Myc axis. J Hematol Oncol.
12:912019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ireland AS, Micinski AM, Kastner DW, Guo
B, Wait SJ, Spainhower KB, Conley CC, Chen OS, Guthrie MR, Soltero
D, et al: MYC drives temporal evolution of small cell lung cancer
subtypes by reprogramming neuroendocrine fate. Cancer Cell.
38:60–78.e12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bakiri L, Hasenfuss SC, Guío-Carrión A,
Thomsen MK, Hasselblatt P and Wagner EF: Liver cancer development
driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc. Proc Natl Acad
Sci USA. 121:e24041881212024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Faskhoudi MA, Molaei P, Sadrkhanloo M,
Orouei S, Hashemi M, Bokaie S, Rashidi M, Entezari M, Zarrabi A,
Hushmandi K, et al: Molecular landscape of c-Myc signaling in
prostate cancer: A roadmap to clinical translation. Pathol Res
Pract. 233:1538512022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao FY, Li XT, Xu K, Wang RT and Guan XX:
c-MYC mediates the crosstalk between breast cancer cells and tumor
microenvironment. Cell Commun Signal. 21:282023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Evan G, Harrington E, Fanidi A, Land H,
Amati B and Bennett M: Integrated control of cell proliferation and
cell death by the c-myc oncogene. Philos Trans R Soc Lond B Biol
Sci. 345:269–275. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boulos JC, Omer EA, Rigano D, Formisano C,
Chatterjee M, Leich E, Klauck SM, Shan LT and Efferth T:
Cynaropicrin disrupts tubulin and c-Myc-related signaling and
induces parthanatos-type cell death in multiple myeloma. Acta
Pharmacol Sin. 44:2265–2281. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang HY, Goldman AR, Zhang X, Speicher DW
and Dang CV: Measuring MYC-mediated metabolism in tumorigenesis.
Methods Mol Biol. 2318:231–239. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sim DY, Lee HJ, Ahn CH, Park J, Park SY,
Kil BJ, Shim BS, Kim B and Kim SH: Negative regulation of CPSF6
suppresses the warburg effect and angiogenesis leading to tumor
progression via c-Myc signaling network: Potential therapeutic
target for liver cancer therapy. Int J Biol Sci. 20:3442–3460.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoshida GJ: Emerging roles of Myc in stem
cell biology and novel tumor therapies. J Exp Clin Cancer Res.
37:1732018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Yang Y, Shao F, Meng Y, Guo D, He
J and Lu Z: Acetate reprogrammes tumour metabolism and promotes
PD-L1 expression and immune evasion by upregulating c-Myc. Nat
Metab. 6:914–932. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Amati B, Brooks MW, Levy N, Littlewood TD,
Evan GI and Land H: Oncogenic activity of the c-Myc protein
requires dimerization with Max. Cell. 72:233–245. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Panova S, Cliff MJ, Macek P, Blackledge M,
Jensen MR, Nissink JWM, Embrey KJ, Davies R and Waltho JP: Mapping
hidden residual structure within the Myc bHLH-LZ domain using
chemical denaturant titration. Structure. 27:1537–1546.e4. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee M, Seok J, Saha SK, Cho S, Jeong Y,
Gil M, Kim A, Shin HY, Bae H, Do JT, et al: Alterations and
co-occurrence of C-MYC, N-MYC, and L-MYC expression are related to
clinical outcomes in various cancers. Int J Stem Cells. 16:215–233.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang C, Zhang J, Yin J, Gan Y, Xu S, Gu Y
and Huang W: Alternative approaches to target Myc for cancer
treatment. Signal Transduct Target Ther. 6:1172021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lama D, Vosselman T, Sahin C, Liaño-Pons
J, Cerrato CP, Nilsson L, Teilum K, Lane DP, Landreh M and Arsenian
Henriksson M: A druggable conformational switch in the c-MYC
transactivation domain. Nat Commun. 15:18652024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Q, West-Osterfield K, Spears E, Li
Z, Panaccione A and Hann SR: MB0 and MBI are independent and
distinct transactivation domains in MYC that are essential for
transformation. Genes (Basel). 8:1342017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kalkat M, Resetca D, Lourenco C, Chan PK,
Wei Y, Shiah YJ, Vitkin N, Tong Y, Sunnerhagen M, Done SJ, et al:
MYC protein interactome profiling reveals functionally distinct
regions that cooperate to drive tumorigenesis. Mol Cell.
72:836–848.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thomas LR, Foshage AM, Weissmiller AM,
Popay TM, Grieb BC, Qualls SJ, Ng V, Carboneau B, Lorey S, Eischen
CM and Tansey WP: Interaction of MYC with host cell factor-1 is
mediated by the evolutionarily conserved Myc box IV motif.
Oncogene. 35:3613–3618. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cowling VH, Chandriani S, Whitfield ML and
Cole MD: A conserved Myc protein domain, MBIV, regulates DNA
binding, apoptosis, transformation, and G2 arrest. Mol Cell Biol.
26:4226–4239. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zinzalla G: Biophysical and structural
methods to study the bHLHZip region of human c-MYC. Methods Mol
Biol. 2318:21–43. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ghasemi N and Azizi H: Exploring Myc
puzzle: Insights into cancer, stem cell biology, and PPI networks.
Gene. 916:1484472024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rahl PB and Young RA: MYC and
transcription elongation. Cold Spring Harb Perspect Med.
4:a0209902014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cargnello M and Topisirovic I: c-Myc
steers translation in lymphoma. J Exp Med. 216:1471–1473. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Amati B, Frank SR, Donjerkovic D and
Taubert S: Function of the c-Myc oncoprotein in chromatin
remodeling and transcription. Biochim Biophys Acta. 1471:M135–M145.
2001.PubMed/NCBI
|
|
47
|
Wang Y, Yang G, Zhang X, Bai R, Yuan D,
Gao D, He Q, Yuan Y, Zhang X, Kou J, et al: Antitumor effect of
anti-c-Myc aptamer-based PROTAC for degradation of the c-Myc
protein. Adv Sci (Weinh). 11:e23096392024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
See YX, Chen K and Fullwood MJ: MYC
overexpression leads to increased chromatin interactions at
super-enhancers and MYC binding sites. Genome Res. 32:629–642.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fatma H, Maurya SK and Siddique HR:
Epigenetic modifications of c-MYC: Role in cancer cell
reprogramming, progression and chemoresistance. Semin Cancer Biol.
83:166–176. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dejure FR and Eilers M: MYC and tumor
metabolism: Chicken and egg. EMBO J. 36:3409–3420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Stratton MR, Campbell PJ and Futreal PA:
The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Martincorena I and Campbell PJ: Somatic
mutation in cancer and normal cells. Science. 349:1483–1489. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, metabolism, and cancer. Cancer Discov.
5:1024–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Baluapuri A, Wolf E and Eilers M: Target
gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell
Biol. 21:255–267. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhao D, Pan C, Sun J, Gilbert C,
Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D,
et al: VEGF drives cancer-initiating stem cells through
VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene.
34:3107–3119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Dadiani M, Seger D, Kreizman T, Badikhi D,
Margalit R, Eilam R and Degani H: Estrogen regulation of vascular
endothelial growth factor in breast cancer in vitro and in vivo:
The role of estrogen receptor alpha and c-Myc. Endocr Relat Cancer.
16:819–834. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhu P, He F, Hou Y, Tu G, Li Q, Jin T,
Zeng H, Qin Y, Wan X, Qiao Y, et al: A novel hypoxic long noncoding
RNA KB-1980E6.3 maintains breast cancer stem cell stemness via
interacting with IGF2BP1 to facilitate c-Myc mRNA stability.
Oncogene. 40:1609–1627. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Klauber-DeMore N, Schulte BA and Wang GY:
Targeting MYC for triple-negative breast cancer treatment.
Oncoscience. 5:120–121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang L, Li J, Li Y, Zhou Y, Wang Z, Zhang
D, Liu J and Zhang X: Diclofenac impairs the proliferation and
glucose metabolism of triple-negative breast cancer cells by
targeting the c-Myc pathway. Exp Ther Med. 21:5842021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yao B, Xing M, Zeng X, Zhang M, Zheng Q,
Wang Z, Peng B, Qu S, Li L, Jin Y, et al: KMT2D-mediated H3K4me1
recruits YBX1 to facilitate triple-negative breast cancer
progression through epigenetic activation of c-Myc. Clin Transl
Med. 14:e17532024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yuan XN, Shao YC, Guan XQ, Liu Q, Chu MF,
Yang ZL, Li H, Zhao S, Tian YH, Zhang JW and Wei L: METTL3
orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in
triple-negative breast cancer. Biochim Biophys Acta Mol Cell Res.
1871:1197162024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li J, Pan J, Liu Y, Luo X, Yang C, Xiao W,
Li Q, Yang L and Zhang X: 3-Bromopyruvic acid regulates glucose
metabolism by targeting the c-Myc/TXNIP axis and induces
mitochondria-mediated apoptosis in TNBC cells. Exp Ther Med.
24:5202022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pan JM, Li JC, Yang C, Xiao WF, Li QS, Luo
XH and Zhang XD: 3-Bromopyruvate inhibits the growth and glucose
metabolism of TNBC xenografts in nude mice by targeting c-Myc.
Anticancer Agents Med Chem. 23:1421–1428. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hsu WJ, Chen CH, Chang YC, Cheng CH, TsaI
YH and Lin CW: PRMT1 confers resistance to olaparib via modulating
MYC signaling in triple-negative breast cancer. J Pers Med.
11:10092021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Öhlund D, Handly-Santana A, Biffi G,
Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA,
Lee EJ, et al: Distinct populations of inflammatory fibroblasts and
myofibroblasts in pancreatic cancer. J Exp Med. 214:579–596. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Han H, Jain AD, Truica MI,
Izquierdo-Ferrer J, Anker JF, Lysy B, Sagar V, Luan Y, Chalmers ZR,
Unno K, et al: Small-molecule MYC inhibitors suppress tumor growth
and enhance immunotherapy. Cancer Cell. 36:483–497.e15. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Michaels AD, Newhook TE, Adair SJ, Morioka
S, Goudreau BJ, Nagdas S, Mullen MG, Persily JB, Bullock TNJ,
Slingluff CL Jr, et al: CD47 blockade as an adjuvant immunotherapy
for resectable pancreatic cancer. Clin Cancer Res. 24:1415–1425.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Pan Y, Lu F, Fei Q, Yu X, Xiong P, Yu X,
Dang Y, Hou Z, Lin W, Lin X, et al: Single-cell RNA sequencing
reveals compartmental remodeling of tumor-infiltrating immune cells
induced by anti-CD47 targeting in pancreatic cancer. J Hematol
Oncol. 12:1242019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Dang CV: MYC, metabolism, cell growth, and
tumorigenesis. Cold Spring Harb Perspect Med. 3:a0142172013.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ganguly K, Bhatia R, Rauth S, Kisling A,
Atri P, Thompson C, Vengoji R, Ram Krishn S, Shinde D, Thomas V, et
al: Mucin 5AC serves as the nexus for β-catenin/c-Myc interplay to
promote glutamine dependency during pancreatic cancer
chemoresistance. Gastroenterology. 162:253–268.e13. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Fang Y, Shen ZY, Zhan YZ, Feng XC, Chen
KL, Li YS, Deng HJ, Pan SM, Wu DH and Ding Y: CD36 inhibits
β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4
to repress colorectal tumorigenesis. Nat Commun. 10:39812019.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fang Y, Zhou W, Rong Y, Kuang T, Xu X, Wu
W, Wang D and Lou W: Exosomal miRNA-106b from cancer-associated
fibroblast promotes gemcitabine resistance in pancreatic cancer.
Exp Cell Res. 383:1115432019. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lin J, Wang X, Zhai S, Shi M, Peng C, Deng
X, Fu D, Wang J and Shen B: Hypoxia-induced exosomal circPDK1
promotes pancreatic cancer glycolysis via c-myc activation by
modulating miR-628-3p/BPTF axis and degrading BIN1. J Hematol
Oncol. 15:1282022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cui G, Huang Y, Feng W, Yao Y, Zhou H, Li
X, Gong H, Liu J, Luo Y, Sun Y, et al: Colon cancer-associated
transcript-1 enhances glucose metabolism and colon cancer cell
activity in a high-glucose environment in vitro and in vivo. J
Gastrointest Oncol. 11:1164–1185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Selem NA, Youness RA and Gad MZ: What is
beyond LncRNAs in breast cancer: A special focus on colon
cancer-associated transcript-1 (CCAT-1). Noncoding RNA Res.
6:174–186. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang J and Gao Y: CCAT-1 promotes
proliferation and inhibits apoptosis of cervical cancer cells via
the Wnt signaling pathway. Oncotarget. 8:68059–68070. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li S, Ma YM, Zheng PS and Zhang P: GDF15
promotes the proliferation of cervical cancer cells by
phosphorylating AKT1 and Erk1/2 through the receptor ErbB2. J Exp
Clin Cancer Res. 37:802018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wan F, Miao X, Quraishi I, Kennedy V,
Creek KE and Pirisi L: Gene expression changes during HPV-mediated
carcinogenesis: A comparison between an in vitro cell model and
cervical cancer. Int J Cancer. 123:32–40. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Li L, Zhang R, Yang H, Zhang D, Liu J, Li
J and Guo B: GDF15 knockdown suppresses cervical cancer cell
migration in vitro through the TGF-β/Smad2/3/Snail1 pathway. FEBS
Open Bio. 10:2750–2760. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Jiang Y, Han Y, Sun C, Han C, Han N, Zhi W
and Qiao Q: Rab23 is overexpressed in human bladder cancer and
promotes cancer cell proliferation and invasion. Tumour Biol.
37:8131–8138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Jiang G and Huang C, Liao X, Li J, Wu XR,
Zeng F and Huang C: The RING domain in the anti-apoptotic protein
XIAP stabilizes c-Myc protein and preserves anchorage-independent
growth of bladder cancer cells. J Biol Chem. 294:5935–5944. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang J, Zhao X, Shi J, Pan Y, Chen Q, Leng
P and Wang Y: miR-451 suppresses bladder cancer cell migration and
invasion via directly targeting c-Myc. Oncol Rep. 36:2049–2058.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lucas CM, Harris RJ, Giannoudis A and
Clark RE: c-Myc inhibition decreases CIP2A and reduces BCR-ABL1
tyrosine kinase activity in chronic myeloid leukemia.
Haematologica. 100:e179–e182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sanchez-Martin M and Ferrando A: The
NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
Blood. 129:1124–1133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Chen JL, Ping YH, Tseng MJ, Chang YI, Lee
HC, Hsieh RH and Yeh TS: Notch1-promoted TRPA1 expression in
erythroleukemic cells suppresses erythroid but enhances
megakaryocyte differentiation. Sci Rep. 7:428832017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Matsushita K, Kitamura K, Rahmutulla B,
Tanaka N, Ishige T, Satoh M, Hoshino T, Miyagi S, Mori T, Itoga S,
et al: Haploinsufficiency of the c-myc transcriptional repressor
FIR, as a dominant negative-alternative splicing model, promoted
p53-dependent T-cell acute lymphoblastic leukemia progression by
activating Notch1. Oncotarget. 6:5102–5117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Qin T, Wang J, Wang J, Du Q, Wang L, Liu
H, Liu W, Li X, Jiang Y, Xu Q, et al: Nuclear to cytoplasmic
transport is a druggable dependency in HDAC7-driven small cell lung
cancer. Adv Sci (Weinh). 12:e24134452025. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Nishida Y, Ishizawa J, Ayoub E, Montoya
RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA,
Khazaei S, et al: Enhanced TP53 reactivation disrupts MYC
transcriptional program and overcomes venetoclax resistance in
acute myeloid leukemias. Sci Adv. 9:eadh14362023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
García-Gutiérrez L, Bretones G, Molina E,
Arechaga I, Symonds C, Acosta JC, Blanco R, Fernández A, Alonso L,
Sicinski P, et al: Myc stimulates cell cycle progression through
the activation of Cdk1 and phosphorylation of p27. Sci Rep.
9:186932019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Niu Z, Liu H, Zhou M, Wang H, Liu Y, Li X,
Xiong W, Ma J, Li X and Li G: Knockdown of c-Myc inhibits cell
proliferation by negatively regulating the Cdk/Rb/E2F pathway in
nasopharyngeal carcinoma cells. Acta Biochim Biophys Sin
(Shanghai). 47:183–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Mao A, Zhao Q, Zhou X, Sun C, Si J, Zhou
R, Gan L and Zhang H: MicroRNA-449a enhances radiosensitivity by
downregulation of c-Myc in prostate cancer cells. Sci Rep.
6:273462016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Seth A, Gupta S and Davis RJ: Cell cycle
regulation of the c-Myc transcriptional activation domain. Mol Cell
Biol. 13:4125–4136. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Hydbring P, Castell A and Larsson LG: MYC
modulation around the CDK2/p27/SKP2 axis. Genes (Basel). 8:1742017.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zhang Y, Li Z, Hao Q, Tan W, Sun J, Li J,
Chen CW, Li Z, Meng Y, Zhou Y, et al: The Cdk2-c-Myc-miR-571 axis
regulates DNA replication and genomic stability by targeting
geminin. Cancer Res. 79:4896–4910. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Henriksson S, Calderón-Montaño JM, Solvie
D, Warpman Berglund U and Helleday T: Overexpressed c-Myc
sensitizes cells to TH1579, a mitotic arrest and oxidative DNA
damage inducer. Biomolecules. 12:17772022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Fan Y, Jia X, Xie T, Zhu L and He F:
Radiosensitizing effects of c-myc gene knockdown-induced G2/M phase
arrest by intrinsic stimuli via the mitochondrial signaling
pathway. Oncol Rep. 44:2669–2677. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Boxer LM and Dang CV: Translocations
involving c-myc and c-myc function. Oncogene. 20:5595–5610. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Bretones G, Delgado MD and León J: Myc and
cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Chen J, Li W, Cui K, Ji K, Xu S and Xu Y:
Artemisitene suppresses tumorigenesis by inducing DNA damage
through deregulating c-Myc-topoisomerase pathway. Oncogene.
37:5079–5087. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Cui F, Fan R, Chen Q, He Y, Song M, Shang
Z, Zhang S, Zhu W, Cao J, Guan H and Zhou PK: The involvement of
c-Myc in the DNA double-strand break repair via regulating
radiation-induced phosphorylation of ATM and DNA-PKcs activity. Mol
Cell Biochem. 406:43–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Fan L, Xu S, Zhang F, Cui X, Fazli L,
Gleave M, Clark DJ, Yang A, Hussain A, Rassool F and Qi J: Histone
demethylase JMJD1A promotes expression of DNA repair factors and
radio-resistance of prostate cancer cells. Cell Death Dis.
11:2142020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Gravina GL, Festuccia C, Popov VM, Di
Rocco A, Colapietro A, Sanità P, Monache SD, Musio D, De Felice F,
Di Cesare E, et al: c-Myc sustains transformed phenotype and
promotes radioresistance of embryonal rhabdomyosarcoma cell lines.
Radiat Res. 185:411–422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Mac Partlin M, Homer E, Robinson H,
McCormick CJ, Crouch DH, Durant ST, Matheson EC, Hall AG, Gillespie
DA and Brown R: Interactions of the DNA mismatch repair proteins
MLH1 and MSH2 with c-MYC and MAX. Oncogene. 22:819–825. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Olave MC and Graham RP: Mismatch repair
deficiency: The what, how and why it is important. Genes
Chromosomes Cancer. 61:314–321. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li Z, Pearlman AH and Hsieh P: DNA
mismatch repair and the DNA damage response. DNA Repair (Amst).
38:94–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Fishel R: Mismatch repair. J Biol Chem.
290:26395–26403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ijsselsteijn R, Jansen JG and de Wind N:
DNA mismatch repair-dependent DNA damage responses and cancer. DNA
Repair (Amst). 93:1029232020. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Bucci B, D'Agnano I, Amendola D, Citti A,
Raza GH, Miceli R, De Paula U, Marchese R, Albini S, Felsani A, et
al: Myc down-regulation sensitizes melanoma cells to radiotherapy
by inhibiting MLH1 and MSH2 mismatch repair proteins. Clin Cancer
Res. 11:2756–2767. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Carey JPW, Karakas C, Bui T, Chen X,
Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK and
Keyomarsi K: Synthetic lethality of PARP inhibitors in combination
with MYC blockade is independent of BRCA status in triple-negative
breast cancer. Cancer Res. 78:742–757. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Kuzyk A and Mai S: c-MYC-induced genomic
instability. Cold Spring Harb Perspect Med. 4:a0143732014.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Das SK, Karmakar S, Venkatachalapathy H,
Jha RK, Batchelor E and Levens D: Excessive MYC-topoisome activity
triggers acute DNA damage, MYC degradation, and replacement by a
p53-topoisome. Mol Cell. 84:4059–4078.e10. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Faubert B, Solmonson A and DeBerardinis
RJ: Metabolic reprogramming and cancer progression. Science.
368:eaaw54732020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Li M, Yu J, Ju L, Wang Y, Jin W, Zhang R,
Xiang W, Ji M, Du W, Wang G, et al: USP43 stabilizes c-Myc to
promote glycolysis and metastasis in bladder cancer. Cell Death
Dis. 15:442024. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Guo X, Zhu Y and Hong X, Zhang M, Qiu X,
Wang Z, Qi Z and Hong X: miR-181d and c-myc-mediated inhibition of
CRY2 and FBXL3 reprograms metabolism in colorectal cancer. Cell
Death Dis. 8:e29582017. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Nieminen AI, Partanen JI, Hau A and
Klefstrom J: c-Myc primed mitochondria determine cellular
sensitivity to TRAIL-induced apoptosis. EMBO J. 26:1055–1067. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Shen S, Yao T, Xu Y, Zhang D, Fan S and Ma
J: CircECE1 activates energy metabolism in osteosarcoma by
stabilizing c-Myc. Mol Cancer. 19:1512020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Hsieh AL, Walton ZE, Altman BJ, Stine ZE
and Dang CV: MYC and metabolism on the path to cancer. Semin Cell
Dev Biol. 43:11–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Xiao L, Hu ZY, Dong X, Tan Z, Li W, Tang
M, Chen L, Yang L, Tao Y, Jiang Y, et al: Targeting Epstein-Barr
virus oncoprotein LMP1-mediated glycolysis sensitizes
nasopharyngeal carcinoma to radiation therapy. Oncogene.
33:4568–4578. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Wise DR, DeBerardinis RJ, Mancuso A, Sayed
N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon
SB and Thompson CB: Myc regulates a transcriptional program that
stimulates mitochondrial glutaminolysis and leads to glutamine
addiction. Proc Natl Acad Sci USA. 105:18782–18777. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Gao P, Tchernyshyov I, Chang TC, Lee YS,
Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT and
Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial
glutaminase expression and glutamine metabolism. Nature.
458:762–765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Peng Y, Fu S, Hu W, Qiu Y, Zhang L, Tan R
and Sun LQ: Glutamine synthetase facilitates cancer cells to
recover from irradiation-induced G2/M arrest. Cancer Biol Ther.
21:43–51. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Fu S, Li Z, Xiao L, Hu W, Zhang L, Xie B,
Zhou Q, He J, Qiu Y, Wen M, et al: Glutamine synthetase promotes
radiation resistance via facilitating nucleotide metabolism and
subsequent DNA damage repair. Cell Rep. 28:1136–1143.e4. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Rashmi R, Jayachandran K, Zhang J, Menon
V, Muhammad N, Zahner M, Ruiz F, Zhang S, Cho K, Wang Y, et al:
Glutaminase inhibitors induce thiol-mediated oxidative stress and
radiosensitization in treatment-resistant cervical cancers. Mol
Cancer Ther. 19:2465–2475. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Zimmerli D, Brambillasca CS, Talens F,
Bhin J, Linstra R, Romanens L, Bhattacharya A, Joosten SEP, Da
Silva AM, Padrao N, et al: MYC promotes immune-suppression in
triple-negative breast cancer via inhibition of interferon
signaling. Nat Commun. 13:65792022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Yao X, Xue Y, Ma Q, Bai Y, Jia P, Zhang Y,
Lai B, He S, Ma Q, Zhang J, et al: 221S-1a inhibits endothelial
proliferation in pathological angiogenesis through ERK/c-Myc
signaling. Eur J Pharmacol. 952:1758052023. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yao J, Huang M, Shen Q, Ding M, Yu S, Guo
Y, Lin Y, Zheng Y, Chen W, Yan W, et al: c-Myc-PD-L1 axis sustained
gemcitabine-resistance in pancreatic cancer. Front Pharmacol.
13:8515122022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Casey SC, Tong L, Li Y, Do R, Walz S,
Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M and Felsher
DW: MYC regulates the antitumor immune response through CD47 and
PD-L1. Science. 352:227–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Liang MQ, Yu FQ and Chen C: C-Myc
regulates PD-L1 expression in esophageal squamous cell carcinoma.
Am J Transl Res. 12:379–388. 2020.PubMed/NCBI
|
|
129
|
Oh ET, Kim CW, Kim HG, Lee JS and Park HJ:
Brusatol-mediated inhibition of c-Myc increases HIF-1α degradation
and causes cell death in colorectal cancer under hypoxia.
Theranostics. 7:3415–3431. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Weili Z, Zhikun L, Jianmin W and Qingbao
T: Knockdown of USP28 enhances the radiosensitivity of esophageal
cancer cells via the c-Myc/hypoxia-inducible factor-1 alpha
pathway. J Cell Biochem. 120:201–212. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Steinbichler TB, Dudás J, Skvortsov S,
Ganswindt U, Riechelmann H and Skvortsova II: Therapy resistance
mediated by cancer stem cells. Semin Cancer Biol. 53:156–167. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Okita K, Ichisaka T and Yamanaka S:
Generation of germline-competent induced pluripotent stem cells.
Nature. 448:313–317. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Aguirre M, Escobar M, Forero Amézquita S,
Cubillos D, Rincón C, Vanegas P, Tarazona MP, Atuesta Escobar S,
Blanco JC and Celis LG: Application of the yamanaka transcription
factors Oct4, Sox2, Klf4, and c-Myc from the laboratory to the
clinic. Genes (Basel). 14:16972023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Chen H, Jin K, Song J, Zuo Q, Yang H,
Zhang Y and Li B: Functional characterization of the Sox2, c-Myc,
and Oct4 promoters. J Cell Biochem. 120:332–342. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Rennoll S and Yochum G: Regulation of MYC
gene expression by aberrant Wnt/β-catenin signaling in colorectal
cancer. World J Biol Chem. 6:290–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Suo S, Zhao D, Li F, Zhang Y,
Rodriguez-Rodriguez S, Nguyen LXT, Ghoda L, Carlesso N, Marcucci G,
Zhang B and Jin J: Homoharringtonine inhibits the NOTCH/MYC pathway
and exhibits antitumor effects in T-cell acute lymphoblastic
leukemia. Blood. 144:1343–1347. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Wang H, Zhang S, Zhang Y, Jia J, Wang J,
Liu X, Zhang J, Song X, Ribback S, Cigliano A, et al: TAZ is
indispensable for c-MYC-induced hepatocarcinogenesis. J Hepatol.
76:123–134. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhong Q, Liu ZH, Lin ZR, Hu ZD, Yuan L,
Liu YM, Zhou AJ, Xu LH, Hu LJ, Wang ZF, et al: The RARS-MAD1L1
fusion gene induces cancer stem cell-like properties and
therapeutic resistance in nasopharyngeal carcinoma. Clin Cancer
Res. 24:659–673. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Das B, Pal B, Bhuyan R, Li H, Sarma A,
Gayan S, Talukdar J, Sandhya S, Bhuyan S, Gogoi G, et al: MYC
regulates the HIF2α stemness pathway via nanog and Sox2 to maintain
self-renewal in cancer stem cells versus non-stem cancer cells.
Cancer Res. 79:4015–4025. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Yang A, Qin S, Schulte BA, Ethier SP, Tew
KD and Wang GY: MYC inhibition depletes cancer stem-like cells in
triple-negative breast cancer. Cancer Res. 77:6641–6650. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Lin CH, Lin C, Tanaka H, Fero ML and
Eisenman RN: Gene regulation and epigenetic remodeling in murine
embryonic stem cells by c-Myc. PLoS One. 4:e78392009. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Beaulieu ME, Jauset T, Massó-Vallés D,
Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF,
Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, et al: Intrinsic
cell-penetrating activity propels Omomyc from proof of concept to
viable anti-MYC therapy. Sci Transl Med. 11:eaar50122019.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Struntz NB, Chen A, Deutzmann A, Wilson
RM, Stefan E, Evans HL, Ramirez MA, Liang T, Caballero F, Wildschut
MHE, et al: Stabilization of the Max homodimer with a small
molecule attenuates Myc-driven transcription. Cell Chem Biol.
26:711–723.e14. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Shao R, Liu C, Xue R, Deng X, Liu L, Song
C, Xie J, Tang H and Liu W: Tumor-derived exosomal ENO2 modulates
polarization of tumor-associated macrophages through reprogramming
glycolysis to promote progression of diffuse large B-cell lymphoma.
Int J Biol Sci. 20:848–863. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Morelli E, Biamonte L, Federico C, Amodio
N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur
MK, Gullà A, et al: Therapeutic vulnerability of multiple myeloma
to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood.
132:1050–1063. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Oprea M and Ionita M: Antisense
oligonucleotides-based approaches for the treatment of multiple
myeloma. Int J Biol Macromol. 291:1391862025. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Mazur PK, Herner A, Mello SS, Wirth M,
Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA,
Vangala D, et al: Author correction: combined inhibition of BET
family proteins and histone deacetylases as a potential
epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat
Med. 30:20902024. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Glover-Cutter K, Larochelle S, Erickson B,
Zhang C, Shokat K, Fisher RP and Bentley DL: TFIIH-associated Cdk7
kinase functions in phosphorylation of C-terminal domain Ser7
residues, promoter-proximal pausing, and termination by RNA
polymerase II. Mol Cell Biol. 29:5455–5464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Coudé MM, Braun T, Berrou J, Dupont M,
Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME,
et al: BET inhibitor OTX015 targets BRD2 and BRD4 and decreases
c-MYC in acute leukemia cells. Oncotarget. 6:17698–17712. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Huang WL, Abudureheman T, Xia J, Chu L,
Zhou H, Zheng WW, Zhou N, Shi RY, Li MH, Zhu JM, et al: CDK9
inhibitor induces the apoptosis of B-cell acute lymphocytic
leukemia by inhibiting c-Myc-mediated glycolytic metabolism. Front
Cell Dev Biol. 9:6412712021. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Cho Y, Park MJ, Kim K, Kim SW, Kim W, Oh S
and Lee JH: Reactive oxygen species-induced activation of
Yes-associated protein-1 through the c-Myc pathway is a therapeutic
target in hepatocellular carcinoma. World J Gastroenterol.
26:6599–6613. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Lahlali T, Plissonnier ML, Romero-López C,
Michelet M, Ducarouge B, Berzal-Herranz A, Zoulim F, Mehlen P and
Parent R: Netrin-1 protects hepatocytes against cell death through
sustained translation during the unfolded protein response. Cell
Mol Gastroenterol Hepatol. 2:281–301.e9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Monsen RC, DeLeeuw LW, Dean WL, Gray RD,
Chakravarthy S, Hopkins JB, Chaires JB and Trent JO: Long promoter
sequences form higher-order G-quadruplexes: An integrative
structural biology study of c-Myc, k-Ras and c-Kit promoter
sequences. Nucleic Acids Res. 50:4127–4147. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Huppert JL and Balasubramanian S:
G-quadruplexes in promoters throughout the human genome. Nucleic
Acids Res. 35:406–413. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Yang D: G-quadruplex DNA and RNA. Methods
Mol Biol. 2035:1–24. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Robinson J, Raguseo F, Nuccio SP, Liano D
and Di Antonio M: DNA G-quadruplex structures: More than simple
roadblocks to transcription? Nucleic Acids Res. 49:8419–8431. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Dhanasekaran R, Park J, Yevtodiyenko A,
Bellovin DI, Adam SJ, Kd AR, Gabay M, Fernando H, Arzeno J, Arjunan
V, et al: MYC ASO impedes tumorigenesis and elicits oncogene
addiction in autochthonous transgenic mouse models of HCC and RCC.
Mol Ther Nucleic Acids. 21:850–859. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Webb MS, Tortora N, Cremese M, Kozlowska
H, Blaquiere M, Devine DV and Kornbrust DJ: Toxicity and
toxicokinetics of a phosphorothioate oligonucleotide against the
c-myc oncogene in cynomolgus monkeys. Antisense Nucleic Acid Drug
Dev. 11:155–163. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Massó-Vallés D and Soucek L: Blocking Myc
to treat cancer: Reflecting on two decades of omomyc. Cells.
9:8832020. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Garralda E, Beaulieu ME, Moreno V,
Casacuberta-Serra S, Martínez-Martín S, Foradada L, Alonso G,
Massó-Vallés D, López-Estévez S, Jauset T, et al: MYC targeting by
OMO-103 in solid tumors: A phase 1 trial. Nat Med. 30:762–771.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Senapedis W, Gallagher KM, Figueroa E,
Farelli JD, Lyng R, Hodgson JG, O'Donnell CW, Newman JV, Pacaro M,
Siecinski SK, et al: Targeted transcriptional downregulation of MYC
using epigenomic controllers demonstrates antitumor activity in
hepatocellular carcinoma models. Nat Commun. 15:78752024.
View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Xu Y, Yu Q, Wang P, Wu Z, Zhang L, Wu S,
Li M, Wu B, Li H, Zhuang H, et al: A selective small-molecule c-Myc
degrader potently regresses lethal c-Myc overexpressing tumors. Adv
Sci (Weinh). 9:e21043442022. View Article : Google Scholar : PubMed/NCBI
|
